Delving into the Latest Updates on Harbour BioMed (Suzhou) Co., Ltd. with Synapse

Overview

Tags

Neoplasms

Immune System Diseases

Urogenital Diseases

Monoclonal antibody

Bispecific antibody

Antibody Fragment-Drug Conjugates (FDCs)

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	7
Immune System Diseases	3
Endocrinology and Metabolic Disease	2
Infectious Diseases	2
Hemic and Lymphatic Diseases	2
Nervous System Diseases	1

Top 5 Drug Type	Count

Monoclonal antibody	6
Bispecific antibody	1
CAR-T	1
Antibody Fragment-Drug Conjugates (FDCs)	1

Top 5 Target	Count

CLDN18.2(Claudin 18.2)	2
CD3 x TAA	1
Siglec-15(Sialic acid-binding Ig-like lectin 15)	1
IL2RA(Interleukin-2 receptor alpha chain)	1
LIFR(LIF receptor subunit alpha)	1

Adverse events and abnormal laboratory indicators during treatment were observed to evaluate the medium- and long-term safety of HBM9161 combined with basic treatment in gMG patients. Improvement of signs and symptoms during treatment was observed to evaluate the medium- and long-term effectiveness of the study drug HBM9161 combined with basic MG treatment.

Start Date30 Jun 2022

Sponsor / Collaborator

Harbour BioMed (Suzhou) Co., Ltd.

[+2]

CTR20212846 / RecruitingPhase 1

一项开放性1期研究，评估HBM4003与特瑞普利单抗联用在晚期肝细胞癌及其他实体瘤患者中的安全性、耐受性、PK/PD和初步疗效

[Translation] An open-label Phase 1 study evaluating the safety, tolerability, PK/PD, and preliminary efficacy of HBM4003 in combination with toripalimab in patients with advanced hepatocellular carcinoma and other solid tumors

第1部分：剂量递增部分，确定HBM4003与特瑞普利单抗联合用药，在晚期肝细胞癌及其他实体瘤患者中的最高耐受剂量（MTD）和/或推荐2期剂量（RP2D）第2部分：剂量扩展部分，评估HBM4003与特瑞普利单抗联合用药，在RP2D剂量下，在晚期肝细胞癌患者的初步疗效及安全性

[Translation]

Part 1: Dose escalation part, to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of HBM4003 combined with toripalimab in patients with advanced hepatocellular carcinoma and other solid tumors Part 2: Dose expansion part, to evaluate the preliminary efficacy and safety of HBM4003 combined with toripalimab at the RP2D dose in patients with advanced hepatocellular carcinoma

Start Date15 Dec 2021

Sponsor / Collaborator

Harbour BioMed (Suzhou) Co., Ltd.

CTR20211287 / CompletedPhase 2

一项随机、双盲、安慰剂对照、2/3期运营无缝设计临床研究以评价HBM9161皮下注射在中国活动性、中度至重度甲状腺眼病（TED）患者中的疗效和安全性

[Translation] A randomized, double-blind, placebo-controlled, Phase 2/3 seamlessly designed clinical study to evaluate the efficacy and safety of subcutaneous HBM9161 in Chinese patients with active, moderate to severe thyroid eye disease (TED)

主要目的：初步评价HBM9161 680 mg皮下注射每周给药及每周给药序贯隔周给药共12周的治疗方案在中国活动性、中重度TED患者中的疗效；次要目的：初步评价HBM9161皮下注射12周在中国TED患者中的安全性，药代动力学（PK），药效学（PD），免疫原性，受试者对研究方案的依从性。

[Translation]

Primary objective: To preliminarily evaluate the efficacy of HBM9161 680 mg subcutaneous injection weekly and weekly followed by alternate weeks for 12 weeks in Chinese patients with active, moderate to severe TED; Secondary objective: To preliminarily evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and compliance of subjects with the study regimen of HBM9161 subcutaneously injected for 12 weeks in Chinese patients with TED.

Start Date07 Oct 2021

Sponsor / Collaborator

Harbour BioMed (Suzhou) Co., Ltd.

[+2]

100 Clinical Results associated with Harbour BioMed (Suzhou) Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Harbour BioMed (Suzhou) Co., Ltd.

Login to view more data

1

Literatures (Medical) associated with Harbour BioMed (Suzhou) Co., Ltd.

PLOS BiologyQ1 · BIOLOGY

Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes

Q1 · BIOLOGY

ArticleOA

Author: Zhang, Zheng ; Rao, Zihe ; Tian, Yujie ; Zhang, Chen ; Lou, Zhiyong ; Zhou, Yunjiao ; Fu, Dan ; Wang, Wei ; Wu, Jun ; Wang, Yuhui ; Liu, Jia ; Hu, Hengrui ; Wang, Manli ; Lu, Zhonghua ; Yu, Feng ; Deng, Fei ; Zhou, Xingdong ; Li, Bo ; Zhang, Hongkai ; Liu, Louis ; Wang, Yuan ; Li, Yufeng ; Fang, Yaohui ; Li, Xin ; Nie, Cui ; Zhou, Liang ; Wang, Xiaoxiao ; Shao, Na ; Wang, Qiao ; Wang, Qisheng ; Zhang, Guangshun ; Shen, Shu ; Chen, Da ; Deng, Changjing ; Guo, Yu ; Guan, Guangkuo ; Chen, Xinwen

The ongoing Coronavirus Disease 2019 (COVID-19) pandemic caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) threatens global public health and economy unprecedentedly, requiring accelerating development of prophylactic and therapeutic interventions. Molecular understanding of neutralizing antibodies (NAbs) would greatly help advance the development of monoclonal antibody (mAb) therapy, as well as the design of next generation recombinant vaccines. Here, we applied H2L2 transgenic mice encoding the human immunoglobulin variable regions, together with a state-of-the-art antibody discovery platform to immunize and isolate NAbs. From a large panel of isolated antibodies, 25 antibodies showed potent neutralizing activities at sub-nanomolar levels by engaging the spike receptor-binding domain (RBD). Importantly, one human NAb, termed PR1077, from the H2L2 platform and 2 humanized NAb, including PR953 and PR961, were further characterized and subjected for subsequent structural analysis. High-resolution X-ray crystallography structures unveiled novel epitopes on the receptor-binding motif (RBM) for PR1077 and PR953, which directly compete with human angiotensin-converting enzyme 2 (hACE2) for binding, and a novel non-blocking epitope on the neighboring site near RBM for PR961. Moreover, we further tested the antiviral efficiency of PR1077 in the Ad5-hACE2 transduction mouse model of COVID-19. A single injection provided potent protection against SARS-CoV-2 infection in either prophylactic or treatment groups. Taken together, these results shed light on the development of mAb-related therapeutic interventions for COVID-19.

100 Deals associated with Harbour BioMed (Suzhou) Co., Ltd.

Login to view more data

100 Translational Medicine associated with Harbour BioMed (Suzhou) Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 08 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

5

2

Preclinical

Phase 1 Clinical

1

NDA/BLA

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Batoclimab ( FcRn )	-	NDA/BLA
Porustobart ( CTLA4 )	Advanced Malignant Solid Neoplasm More	Phase 1
CLDN-18.2 targets CAR-T (Nonna Biology) ( CLDN18.2 )	Neoplasms More	Preclinical
HBICE-4-mRNA ( CD3 x TAA )	Neoplasms More	Preclinical
WO2022211508 ( CLDN18.2 )	Neoplasms More	Discovery